|
|
|
Executives at Big Pharma and small biotech will be rewarded in 2024 if they can find new ways to develop and commercialize drugs in the context of an unforgiving investment, payer, and regulatory landscape. |
|
|
|
Executives responding to this year’s finance and funding outlook questions are optimistic about the potential for a turnaround in 2024. |
|
|
|
Biopharmaceutical companies can’t afford to halt production lines due to manufacturing violations next year. Manufacturing and supply chain processes will require fresh thinking and flexibility in 2024. |
|
|
|
|
|
|
|
|
Inside you will find more on: - Clinical Trial Site Challenges
- Real-World Data
- Outsourcing
- Next Generation Vectors
View the digital edition. |
|
|
CONTRIBUTE TO LIFE SCIENCE LEADER |
|
|
|
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director. |
|
|
Connect With Life Science Leader: |
|
|
|